Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Haloperidol lactate
Drug ID BADD_D01056
Description Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide.[A180616] While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain,[A27477] it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states.[F4645] It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is theorized to be caused by a hyperdopaminergic state within the limbic system of the brain.[A34360] Use of the first-generation antipsychotics (including haloperidol) is considered highly effective for the management of the "positive" symptoms of schizophrenia including hallucinations, hearing voices, aggression/hostility, disorganized speech, and psychomotor agitation. However, this class of drugs is also limited by the development of movement disorders induced by dopamine-blockade such as drug-induced parkinsonism, akathisia, dystonia, tardive dyskinesia, as well as other side effects including sedation, weight gain, and prolactin changes. While there are limited high-quality studies comparing haloperidol to lower-potency first-generation antipsychotics such as [DB00477], [DB01624], [DB00623], and [DB01403], haloperidol typically demonstrates the least amount of side effects within this class, but demonstrates a stronger disposition for causing extrapyramidal symptoms (EPS).[A180613, A180616, A180625] These other low‐potency antipsychotics are limited by their lower affinity for dopamine receptors, which requires a higher dose to effectively treat symptoms of schizophrenia. In addition, they block many receptors other than the primary target (dopamine receptors), such as cholinergic or histaminergic receptors, resulting in a higher incidence of side effects such as sedation, weight gain, and hypotension. Interestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic _CYP2D6_ activity. However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo. Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations.[A32346] First-generation antipsychotic drugs have largely been replaced with second- and third-generation (atypical) antipsychotics such as [DB00734], [DB00334], [DB00363], [DB01224], [DB01238], and [DB00246]. However, haloperidol use remains widespread and is considered the benchmark for comparison in trials of the newer generation antipsychotics.[A180625] The efficacy of haloperidol was first established in controlled trials in the 1960s.[A180610]
Indications and Usage For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioral problems in children with disruptive behavior disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of non-retractable nausea and vomiting.
Marketing Status Prescription; Discontinued
ATC Code N05AD01
DrugBank ID DB00502
KEGG ID D08035
MeSH ID D006220
PubChem ID 16051968
TTD Drug ID D0D1AL
NDC Product Code 25021-806; 63323-474; 76045-737; 0143-9319; 70518-1053; 0143-9501; 17478-110; 55154-9553; 55154-7478; 0143-9502; 67457-426; 70518-0776; 51662-1524; 55154-7076
Synonyms Haloperidol | Haldol
Chemical Information
Molecular Formula C24H29ClFNO5
CAS Registry Number 53515-91-6
SMILES CC(C(=O)O)O.C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionBrain-derived neurotrophic factorP21237Not AvailableNot Available
Adverse drug reactionBrain-derived neurotrophic factorP23560T93122Not Available
ApoptosisMitogen-activated protein kinase 8P45983T40097Not Available
ApoptosisMitogen-activated protein kinase 14Q16539T65864Not Available
ParkinsonismNADH-ubiquinone oxidoreductase chain 1P03886Not AvailableNot Available
Seizures (incl subtypes)G protein-activated inward rectifier potassium channel 1P48549T38012Not Available
Sinus tachycardiaG protein-activated inward rectifier potassium channel 1P48549T38012Not Available
StereotypySuperoxide dismutase [Cu-Zn]P00441T22977Not Available
StereotypyCatalaseP04040T01597Not Available
Tardive dyskinesiaSodium-dependent serotonin transporterP31645T27812Not Available
Tardive dyskinesiaD(2) dopamine receptorP14416T67162Not Available
Tardive dyskinesiaD(4) dopamine receptorP21917T24983Not Available
Tardive dyskinesiaD(3) dopamine receptorP35462T02551Not Available
Tardive dyskinesiaD(1A) dopamine receptorP21728T22118Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Akathisia19.06.02.006; 17.01.02.002--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anxiety19.06.02.002--
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Breast pain21.05.05.003--
Bronchospasm22.03.01.004; 10.01.03.012--
Cataract06.06.01.001--
Catatonia19.11.01.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Death08.04.01.001--
Depression19.15.01.001--
Dermatitis acneiform23.02.01.004--
Diarrhoea07.02.01.001--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Dystonia17.01.03.001--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electrocardiogram QT prolonged13.14.05.004--
Emotional disorder19.04.02.005--Not Available
Euphoric mood19.04.02.006--
Extrapyramidal disorder17.01.02.007--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Hallucination19.10.02.002--
Headache17.14.01.001--
The 1th Page    1 2 3    Next   Last    Total 3 Pages